Study of Treatment Adherence and Patterns in Women with Early-stage HER2-positive Breast Cancer in Serbia After Decentralizing Treatment

What this Trial Is About

Researchers are assessing how a decentralized treatment model affects treatment adherence in people with early-stage HER2-positive breast cancer. The study compares patients who have consistent travel requirements for their adjuvant therapy with those who face increased travel burdens, aiming to understand the impact on treatment patterns and quality of life. Participants are divided into two main groups based on their travel burden during adjuvant therapy. Group 1 includes Cohorts A, C, and D, where treatment location does not increase travel needs, while Group 2 includes Cohort B, where patients must travel from a secondary to a tertiary center. All treatment decisions are made by the treating physician and participant following routine clinical practice without additional interventions mandated by the study. During the study, participants are observed for treatment adherence, completion rates, delays in dosing, travel burden, and quality of life using questionnaires like the EORTC QLQ-C30. Data on timing of neoadjuvant treatment, surgery, and adjuvant treatment initiation are collected. The study will follow participants for up to 2.25 years to monitor these outcomes and understand the effects of treatment decentralization.

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization